Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Valeria Merz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2120-1923; OpenAlex author ID A5073612690. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: none · 2026: 2 papers

Papers 19

  1. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … First author DOI 10.1016/j.esmoop.2026.106964↗
  2. Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-026-01442-w↗
  3. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.05.547↗
  4. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  5. CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-024-00742-3↗
  6. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-0104↗
  7. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. Last author DOI 10.1177/17588359241234487↗
  8. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1002/cam4.6111↗
  9. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Co-author DOI 10.3389/fsurg.2022.866173↗
  10. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  11. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Co-author DOI 10.3390/diagnostics11112166↗
  12. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0395↗
  13. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0270↗
  14. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  15. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051131↗
  16. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  17. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cance… Co-author DOI 10.1007/s00280-019-03931-1↗
  18. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. Co-author DOI 10.1038/ijo.2017.285↗
  19. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1322242↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davide Melisi · 18 shared papers, 2017–2026 · strength 2.60
  2. Simona Casalino · 11 shared papers, 2020–2026 · strength 2.01
  3. Silvia Pietrobono · 8 shared papers, 2022–2026 · strength 1.69
  4. Enza Scarlato · 4 shared papers, 2024–2026 · strength 0.90
  5. Roberto Salvia · 4 shared papers, 2019–2026 · strength 0.55
  6. Giovanni Butturini · 3 shared papers, 2020–2026 · strength 0.48
  7. Francesca Simionato · 6 shared papers, 2017–2020 · strength 0.47
  8. Aldo Scarpa · 4 shared papers, 2017–2024 · strength 0.38
  9. Giuseppe Malleo · 4 shared papers, 2017–2024 · strength 0.35
  10. Claudio Bassi · 4 shared papers, 2017–2024 · strength 0.35
  11. Raffaela Santoro · 4 shared papers, 2017–2020 · strength 0.33
  12. Geny Piro · 4 shared papers, 2017–2020 · strength 0.33
  13. Michèle Milella · 3 shared papers, 2020–2023 · strength 0.32
  14. Alessandro Esposito · 3 shared papers, 2019–2024 · strength 0.29
  15. Mirko D’Onofrio · 3 shared papers, 2019–2024 · strength 0.29
  16. Giovanni Marchegiani · 3 shared papers, 2019–2024 · strength 0.29
  17. Sara Lonardi · 2 shared papers, 2020–2023 · strength 0.23
  18. Ivelina Gueorguieva · 2 shared papers, 2019–2021 · strength 0.20
  19. Karim Adnane Benhadji · 2 shared papers, 2019–2021 · strength 0.20
  20. Teresa Mercade Macarulla · 2 shared papers, 2019–2021 · strength 0.20
  21. Roberto Cannella · 1 shared paper, 2021 · strength 0.17
  22. Massimo Midiri · 1 shared paper, 2021 · strength 0.17
  23. Federica Vernuccio · 1 shared paper, 2021 · strength 0.17
  24. Riccardo De Robertis · 1 shared paper, 2024 · strength 0.15
  25. Stefano Francesco Crinò · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.